Molecular imaging in sporadic alzheimer's disease populations and those genetically at risk

Neurodegenerative Diseases

Volumn 13, Issue 2-3, 2014, Pages 160-162

  Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Amyloid; Mild cognitive impairment; Molecular imaging; Positron emission tomography; Positron emission tomography tracers

Indexed keywords

AMYLOID; BENZODIAZEPINE RECEPTOR; CARBON 11; GLUCOSE; TRACER;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTOSIS; COGNITION; DIAGNOSTIC VALUE; DISEASE COURSE; GENETIC RISK; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; MICROGLIA; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; AMYLOID PLAQUE; BRAIN METABOLISM; BRAIN REGION; CELL ACTIVATION; CONFERENCE PAPER; FOLLOW UP; FRONTAL CORTEX; GENETICS; HIGH RISK POPULATION; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PROTEIN EXPRESSION; RISK FACTOR;

ALZHEIMER DISEASE; BRAIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS;

EID: 84896726072     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000356333     Document Type: Article

References (24)

1. Nordberg A, Rinne J, Kadir A, Långström B: The use of PET in Alzheimer's disease. Nat Rev Neurol 2010; 6: 68-87.
2. Ni R, Gillberg P-G, Bergfors A, Marutle A, Nordberg A: Amyloid tracers detect multiple binding sites in Alzheimer's disease tissue. Brain 2013; 136: 2217-2227.
3. Dubois B, Feldman HH, Jacova C, et al: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
4. Dubois B, Feldman HH, Jacova C, et al: Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127.
5. McKhann GM, Knopman DS, Chertkow H, et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269.
6. Albert MS, DeKosky ST, Dickson D, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279.
7. Sperling RA, Aisen PS, Beckett LA, et al: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute of Aging-Alzheimer Association workgroups on the diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
8. Nordberg A: Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther 2011; 3: 34.
9. Nordberg A, Carter S, Rinne J, et al: A European multi-center PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2013; 40: 104-114.
10. Engler H, Forsberg A, Almkvist O, Blomqvist G, Larsson E, Savicheva I, Wall A, Ringheim A, Långström B, Nordberg A: Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-2866.
11. Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Långström B, Nordberg A: Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012; 33: 198.e1-e14.
12. Jack CR, Wiste HJ, Lesnick TG, et al: Brain β-amyloid load approaches a plateau. Neurology 2013; 80: 1-7.
13. Villemagne VI, Burnham S, Bourgeat P, et al: Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 13: 357-367.
14. 18 F-FDG. J Nucl Med 2012; 53: 37-46.
15. 3 H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain. J Neuroinflamm 2013; 10: 90.
16. Beach TG, McGeer EG: Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer's disease visual cortex. Brain Res 1988; 463: 357-361.
17. Cagnin A, Brooks D, Kennedy A, Gunn R, Myers R, Turkheimer F, Jones T, Banati R: Invivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-467.
18. Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, Mathis CA: Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009; 66: 60-67.
19. Kreisler WC, Hyoung-Lyoo C, MCGwier M, Snow J, Kimberly J, et al: In vivo radioligand binding to translocated protein correlates with severity of Alzheimer's disease. Brain 2013; 136: 2228-2238.
20. Batesman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, et al: Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 365: 795-804.
21. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, et al: Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autsomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol 2012; 11: 1057-1065.
22. Schöll M, Almkvist O, Axelman K, Stefanova E, Wall A, Westman E, Långström B, Lannfelt L, Graff C, Nordberg A: Glucose metabolism and PIB binding in carriers of His163Tyr presenilin 1 mutation. Neurobiol Aging 2011; 32: 1388-1399.
23. Nordberg A: A decade of amyloid imaging: advances in neuroinflammation. Neurobiol Aging 2012; 33(suppl 1):S26.
24. Schöll M, Wall A, Thordadottir S, Ferreira D, Bogdanovic N, Långström B, Almkvist O, Graff C, Nordberg A: Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutations carriers. Neurology 2012; 79: 229-236.